keyword
MENU ▼
Read by QxMD icon Read
search

Sbrt liver

keyword
https://www.readbyqxmd.com/read/28796864/individualized-adaptive-stereotactic-body-radiotherapy-for-liver-tumors-in-patients-at-high-risk-for-liver-damage-a-phase-2-clinical-trial
#1
Mary Feng, Krithika Suresh, Matthew J Schipper, Latifa Bazzi, Edgar Ben-Josef, Martha M Matuszak, Neehar D Parikh, Theodore H Welling, Daniel Normolle, Randall K Ten Haken, Theodore S Lawrence
Importance: Patients with preexisting liver dysfunction could benefit the most from personalized therapy for liver tumors to balance maximal tumor control and minimal risk of liver failure. We designed an individualized adaptive trial testing the hypothesis that adapting treatment based on change in liver function could optimize the therapeutic index for each patient. Objective: To characterize the safety and efficacy of individualized adaptive stereotactic body radiotherapy (SRBT) for liver tumors in patients who have preexisting liver dysfunction...
August 10, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28740893/stereotactic-body-radiotherapy-sbrt-for-locally-advanced-extrahepatic-and-intrahepatic-cholangiocarcinoma
#2
Kiri A Sandler, Darlene Veruttipong, Vatche G Agopian, Richard S Finn, Johnny C Hong, Fady M Kaldas, Saeed Sadeghi, Ronald W Busuttil, Percy Lee
OBJECTIVES: We report single-institution clinical efficacy and safety outcomes for patients with unresectable locally advanced cholangiocarcinoma who were treated with stereotactic body radiation therapy (SBRT) and a subset of patients who received neoadjuvant SBRT and chemotherapy as part of an orthotopic liver transplantation (OLT) protocol. METHODS AND MATERIALS: From October 2008 to June 2015, 31 consecutive patients with unresectable extrahepatic (n = 25) or intrahepatic (n = 6) cholangiocarcinoma were treated with SBRT and retrospectively analyzed...
October 2016: Advances in Radiation Oncology
https://www.readbyqxmd.com/read/28736648/the-utility-of-positron-emission-tomography-computed-tomography-in-target-delineation-for-stereotactic-body-radiotherapy-for-liver-metastasis-from-primary-gastric-cancer-an-illustrative-case-report-and-literature-review
#3
Gary D Lewis, Stephen B Chiang, E Brian Butler, Bin S Teh
The liver is a common site for metastatic disease for many cancers. Radiation therapy is one means of treatment for liver metastases, especially for patients unable to undergo surgery or ineligible for systemic chemotherapy. In particular, stereotactic body radiotherapy (SBRT) has become an important option in the treatment of metastatic disease in the liver. SBRT delivers ablative doses of radiation in relatively few fractions. As such, precise and clear imaging plays an important role in maximizing disease control while minimizing normal tissue toxicity...
June 2017: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/28712715/split-vmat-technique-to-control-the-expiratory-breath-hold-time-in-liver-stereotactic-body-radiation-therapy
#4
Yen Hwa Lin, Shuichi Ozawa, Hideharu Miura, Katsunori Yogo, Takeo Nakashima, Kentaro Miki, Shintaro Tsuda, Yusuke Ochi, Daisuke Kawahara, Tomoki Kimura, Akito Saito, Yasushi Nagata
PURPOSE: In this study, we demonstrate the feasibility of using split-arcs in volumetric modulated arc therapy (VMAT), tailored for expiratory breath-hold in stereotactic body radiation therapy (SBRT) for liver tumors. We compare it with three-dimensional conformal radiation therapy (3D-CRT) and continuous-VMAT, for ten randomly selected hepatocellular carcinoma cases. METHODS: Four coplanar and four non-coplanar beams were used for the 3D-CRT plans. A pair of partial arcs, chosen using a back-and-forth rotating motion, were used for the continuous-VMAT plans...
July 13, 2017: Physica Medica: PM
https://www.readbyqxmd.com/read/28712274/stereotactic-body-radiation-therapy-for-liver-oligo-recurrence-and-oligo-progression-from-various-tumors
#5
Yu Jin Cha, Mi-Sook Kim, Won-Il Jang, Young Seok Seo, Chul Koo Cho, Hyung Jun Yoo, Eun Kyung Paik
PURPOSE: To evaluate the outcomes of stereotactic body radiation therapy (SBRT) for patients with liver oligo-recurrence and oligo-progression from various primary tumors. MATERIALS AND METHODS: Between 2002 and 2013, 72 patients with liver oligo-recurrence (oligo-metastasis with a controlled primary tumor) and oligo-progression (contradictory progression of a few sites of disease despite an overall tumor burden response to therapy) underwent SBRT. Of these, 9 and 8 patients with uncontrollable distant metastases and patients immediate loss to follow-up, respectively, were excluded...
June 2017: Radiation Oncology Journal
https://www.readbyqxmd.com/read/28711479/identification-of-the-suitable-leaf-margin-for-liver-stereotactic-body-radiotherapy-with-flattening-filter-free-beams
#6
Toshiyuki Ogata, Hideki Nishimura, Hiroshi Mayahara, Kazuyuki Uehara, Takanobu Okayama
The purpose of this study is to identify the suitable leaf margin for liver stereotactic body radiotherapy (SBRT) with flattening filter-free (FFF) beams, as compared with that with flattening filter (FF) beams. SBRT treatment planning for 10 patients with liver cancer was performed using 10-MV FFF and FF beams obtained from a Varian TrueBeam (Varian Medical Systems, Palo Alto, CA) linear accelerator. Each plan was generated with the leaf margin to the planning target volume (PTV) ranging from -3 to 5 mm...
July 12, 2017: Medical Dosimetry: Official Journal of the American Association of Medical Dosimetrists
https://www.readbyqxmd.com/read/28710606/sbrt-for-hepatocellular-carcinoma-8-year-experience-from-a-regional-transplant-center
#7
Haoming Qiu, Michael J Moravan, Michael T Milano, Kenneth Y Usuki, Alan W Katz
PURPOSE: The study aimed to evaluate stereotactic body radiotherapy (SBRT) for hepatocellular carcinoma (HCC) in patients not eligible for liver transplant (LT). METHODS: We retrospectively identified transplant-ineligible HCC patients treated with SBRT to the liver between 2004 and 2013. Our primary endpoint was overall survival (OS). We also report treatment toxicities using CTCAE 3.0, radiographic response, and patterns of failure. RESULTS: We identified 93 patients with median age at SBRT of 65...
July 14, 2017: Journal of Gastrointestinal Cancer
https://www.readbyqxmd.com/read/28707533/role-of-extracranial-stereotactic-body-radiation-therapy-in-the-management-of-stage-iv-melanoma
#8
Davide Franceschini, Ciro Franzese, Fiorenza De Rose, Pierina Navarria, Giuseppe R D'Agostino, Tiziana Comito, Angelo Tozzi, Maria C Tronconi, Lorenza Di Guardo, Michele Del Vecchio, Marta Scorsetti
OBJECTIVES: To investigate the role of extracranial stereotactic body radiation therapy (SBRT) in the management of oligometastatic melanoma. METHODS: Patients affected by stage IV melanoma, with less than three extracranial metastatic lesions, who received SBRT were included in this analysis. Acute and late toxicity, local control (LC), overall survival (OS) and progression free survival (PFS) were analyzed. RESULTS: Thirty one patients were included in the study...
July 14, 2017: British Journal of Radiology
https://www.readbyqxmd.com/read/28701219/excellent-local-control-and-tolerance-profile-after-stereotactic-body-radiotherapy-of-advanced-hepatocellular-carcinoma
#9
Eleni Gkika, Michael Schultheiss, Dominik Bettinger, Lars Maruschke, Hannes Philipp Neeff, Michaela Schulenburg, Sonja Adebahr, Simon Kirste, Ursula Nestle, Robert Thimme, Anca-Ligia Grosu, Thomas Baptist Brunner
BACKGROUND: To evaluate the efficacy and toxicity of stereotactic body radiotherapy (SBRT) in the treatment of advanced hepatocellular carcinoma (HCC). MATERIAL AND METHODS: Patients with large HCCs (median diameter 7 cm, IQR 5-10 cm) with a Child-Turcotte-Pugh (CTP) score A (60%) or B (40%) and Barcelona-Clinic Liver Cancer (BCLC) classification stage B or C were treated with 3 to 12 fractions to allow personalized treatment according to the size of the lesions and the proximity of the lesions to the organs at risk aiming to give high biologically equivalent doses assuming an α/β ratio of 10 Gy for HCC...
July 12, 2017: Radiation Oncology
https://www.readbyqxmd.com/read/28693191/effect-of-primary-tumor-location-and-tumor-size-on-the-response-to-radiotherapy-for-liver-metastases-from-colorectal-cancer
#10
Hiroshi Doi, Kenji Uemoto, Osamu Suzuki, Koichi Yamada, Norihisa Masai, Daisaku Tatsumi, Hiroya Shiomi, Ryoong-Jin Oh
Metastatic liver tumors (MLTs) from colorectal cancer (CRC) are often treated with stereotactic body radiation therapy (SBRT). The present study aimed to examine the predictive factors for response of MLTs to SBRT. A total of 39 MLTs from 24 patients with CRC were retrospectively analyzed. Radiotherapy for MLT was typically performed with a prescribed dose equivalent to a biologically effective dose (BED)10 of 100 Gy. The median follow-up period was 16 months (range, 5-64 months). The median prescribed dose and total BED10 were 56 Gy (range, 45-72 Gy) and 97...
July 2017: Oncology Letters
https://www.readbyqxmd.com/read/28636658/efficacy-and-safety-of-ultrasound-guided-implantation-of-fiducial-markers-in-the-liver-for-stereotactic-body-radiation-therapy
#11
So Hyun Park, Hyung Jin Won, So Yeon Kim, Yong Moon Shin, Pyo Nyun Kim, Sang Min Yoon, Jin-Hong Park, Jong Hoon Kim
OBJECTIVE: Stereotactic body radiation therapy (SBRT) for the treatment of a malignancy in the liver requires the perilesional implantation of fiducial markers for lesion detection. The purpose of this study is to evaluate the efficacy and safety of ultrasound (US) -guided marker implantation for SBRT. METHODS: We retrospectively reviewed 299, US-guided, intrahepatic fiducial markers implanted in 101 patients between November 2013 and September 2014. SBRT-planning CT images were analyzed to determine the technical success of the implantation, the mean distance between the tumor margin and the marker, with the ideal location of fiducials defined as the distance between a marker and a tumor less than 3 cm and the distance between markers greater than 2 cm according to the tumor conspicuity seen on gray-scale US and the artifact obscuring tumor margins...
2017: PloS One
https://www.readbyqxmd.com/read/28612018/treatment-options-in-oligometastatic-disease-stereotactic-body-radiation-therapy-focus-on-colorectal-cancer
#12
REVIEW
Aaron T Wild, Yoshiya Yamada
BACKGROUND: Improvements in systemic therapy for metastatic colorectal cancer (CRC) have markedly extended survival, rendering local control of metastases to critical organs of increasing importance, especially in the oligometastatic setting where the disease may not yet have acquired the ability to widely disseminate. While surgical resection remains the gold standard for oligometastases in many organs, stereotactic body radiation therapy (SBRT) presents a non-invasive alternative for achieving local control...
March 2017: Visceral Medicine
https://www.readbyqxmd.com/read/28605745/current-standard-and-future-perspectives-in-non-surgical-therapy-for-hepatocellular-carcinoma
#13
Tobias Eggert, Tim F Greten
BACKGROUND: Hepatocellular carcinoma (HCC) is an aggressive liver tumor with a poor 5-year survival rate. Many HCCs are not amenable to surgical resection, because of tumor size, location, or because of the patient's poor liver function, a common obstacle to HCC therapy, because HCCs almost always develop in chronically inflamed livers. SUMMARY: In recent years, many efforts have been made to improve patient survival by conducting clinical trials investigating local and systemic treatment options for patients with unresectable tumors...
2017: Digestion
https://www.readbyqxmd.com/read/28588789/curative-effect-of-stereotactic-body-radiotherapy-for-unresectable-massive-primary-liver-cancer
#14
Ya-Zheng Dang, Xin Li, Shi-Gao Huang, Wan-Ling Lu, Guodong Wang, Dongxian Zhang, Qian-Yun Wang
The aim of this study was to evaluate the curative effect of gamma knife stereotactic body radiotherapy (SBRT) for unresectable massive primary liver cancer. A total of 69 patients with unresectable massive (>10 cm) primary liver cancer who were treated by SBRT at the Department of Radiation Oncology of the 323 Hospital of People's Liberation Army (Xi'an, China) between October, 2006 and October, 2010, were analyzed. According to the Union for International Cancer Control TNM staging guidelines, the patients were graded as stage T1 (n=8), T2 (n=12), T3 (n=21) and T4 (n=28)...
June 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/28579341/percutaneous-ultrasound-guided-fiducial-marker-placement-for-liver-cancer-robotic-stereotactic-radio-surgery-treatment-a-comparative-analysis-of-three-types-of-markers-and-needles
#15
Maria Marsico, Tommaso Gabbani, Sarah Lunardi, Andrea Galli, Maria Rosa Biagini, Vito Annese
BACKGROUND AND STUDY AIMS: Percutaneous placement of fiducial markers is required to perform stereotactic body radiation therapy (SBRT) for liver neoplastic lesions. This prospective trial was designed to evaluate the feasibility and safety of percutaneous ultrasound-guided placement of three different types of markers in patients with liver cancer referred for SBRT. PATIENTS AND METHODS: Fifty patients underwent percutaneous ultrasound-guided implantation of a fiducial marker in the liver...
June 1, 2017: Arab Journal of Gastroenterology: the Official Publication of the Pan-Arab Association of Gastroenterology
https://www.readbyqxmd.com/read/28577832/advances-in-stereotactic-body-radiation-therapy-for-hepatocellular-carcinoma
#16
REVIEW
Louise J Murray, Laura A Dawson
Stereotactic Body Radiation Therapy (SBRT) is an emerging effective treatment for hepatocellular carcinoma (HCC) associated with acceptable rates of toxicity in appropriately selected patients. Despite often being reserved for patients unsuitable for other local treatments, prospective and retrospective studies have demonstrated excellent long-term control. SBRT may be used as a stand-alone treatment, or as an adjunct to other HCC therapies. Based on available data, SBRT appears to complement existing local liver therapies...
July 2017: Seminars in Radiation Oncology
https://www.readbyqxmd.com/read/28577827/normal-tissue-constraints-for-abdominal-and-thoracic-stereotactic-body-radiotherapy
#17
REVIEW
Erqi L Pollom, Alexander L Chin, Maximilian Diehn, Billy W Loo, Daniel T Chang
Although stereotactic body radiotherapy (SBRT) or stereotactic ablative radiotherapy has become an established standard of care for the treatment of a variety of malignancies, our understanding of normal tissue dose tolerance with extreme hypofractionation remains immature. Since Timmerman initially proposed normal tissue dose constraints for SBRT in the 2008 issue of Seminars of Radiation Oncology, experience with SBRT has grown, and more long-term clinical outcome data have been reported. This article reviews the modern toxicity literature and provides updated clinically practical and useful recommendations of SBRT dose constraints for extracranial sites...
July 2017: Seminars in Radiation Oncology
https://www.readbyqxmd.com/read/28574221/validation-of-a-method-for-in%C3%A2-vivo-3d-dose-reconstruction-in-sbrt-using-a-new-transmission-detector
#18
Yuji Nakaguchi, Takeshi Ono, Masato Maruyama, Yoshinobu Shimohigashi, Yudai Kai
Stereotactic body radiation therapy (SBRT) involves the delivery of substantially larger doses over fewer fractions than conventional therapy. Therefore, SBRT treatments will strongly benefit patients using vivo patient dose verification, because the impact of the fraction is large. For in vivo measurements, a commercially available quality assurance (QA) system is the COMPASS system (IBA Dosimetry, Germany). For measurements, the system uses a new transmission detector (Dolphin, IBA Dosimetry). In this study, we evaluated the method for in vivo 3D dose reconstruction for SBRT using this new transmission detector...
June 2, 2017: Journal of Applied Clinical Medical Physics
https://www.readbyqxmd.com/read/28557541/tracking-sbrt-for-liver-tumors-with-a-gimbaled-linac-system-a-single-institution-experience
#19
Shin-Hyung Park, Jae-Chul Kim
No abstract text is available yet for this article.
May 30, 2017: Acta Oncologica
https://www.readbyqxmd.com/read/28507460/validation-of-the-liver-mean-dose-in-terms-of-the-biological-effective-dose-for-the-prevention-of-radiation-induced-liver-damage
#20
Hiroshi Doi, Norihisa Masai, Kenji Uemoto, Osamu Suzuki, Hiroya Shiomi, Daisaku Tatsumi, Ryoong-Jin Oh
AIM: The purpose of this study was to determine the optimal mean liver biologically effective dose (BED) to prevent radiation-induced liver disease (RILD) in stereotactic body radiation therapy (SBRT). BACKGROUND: The actual mean doses appropriate for liver irradiation in modern radiotherapy techniques have not been adequately investigated, although SBRT is sometimes alternatively performed using fractionated regimens. MATERIALS AND METHODS: SBRT treatment plans for liver tumors in 50 patients were analyzed...
July 2017: Reports of Practical Oncology and Radiotherapy
keyword
keyword
107557
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"